Bundibugyo Ebola · the DR Congo outbreak and the cartridge used in Bunia in May 2026

Zaire Bundibugyo detection threshold

The May cartridge said no

When Bunia samples were tested in May 2026, the Xpert Ebola cartridge used there looked for Zaire ebolavirus, not Bundibugyo. Since then, WHO has listed molecular BDBV tests for emergency use, including a separate panel for GeneXpert Dx; the FDA has separately issued an emergency-use authorization for an antigen test. The listings do not confirm what is available in any particular laboratory in DR Congo.

  • 6known species of ebolavirus
  • 4cause disease in people
  • 1has a licensed vaccine

DR Congo · as of 7 November 2026, the National Institute of Public Health reports 10,920 confirmed cases and 5,323 confirmed deaths. The tally may be revised.

Bunia, May 2026

The May cartridge was right

When people in Ituri started dying with high fever and bleeding, their samples went to the Provincial Public Health Laboratory in Bunia and into a . The machine said negative.

Days later the same samples came back positive on a that looks for every filovirus at once, run in a reference laboratory. On 22 May WHO said GeneXpert could not detect Bundibugyo. In the May 2026 Bunia outbreak account, this referred to the Xpert Ebola cartridge used there, which was designed for Zaire ebolavirus; other cartridges and tests have different indications.

The cartridge was not broken. It was looking for sequences from Zaire ebolavirus, because Zaire ebolavirus is what it was designed for, and the samples from Bunia did not contain Zaire ebolavirus. Confirmation and isolation were delayed. The outbreak was found so late that it began with more cases than any Ebola outbreak on record.

The Xpert Ebola cartridge used in Bunia in May did not detect Bundibugyo.This article’s explanation, based on WHO’s Bunia report of 22 May 2026
Three defences

Three doors

Choose an Ebola virus species. The test door reconstructs the Xpert Ebola cartridge used in Bunia in May 2026; the other doors show the vaccine and drugs with relevant authorization.

The testthe door stays shut
The vaccinethe door stays shut
The drugthe door stays shut
Comparison for disease-causing species; the test door is the cartridge used in Bunia in May 2026
SpeciesCartridge used in Bunia in May 2026Licensed vaccineApproved drug
Zaireyesyesyes
Sudannonono
Bundibugyononono
Taï Forestnonono

The flat line illustrates the negative result from the Xpert Ebola cartridge used in Bunia in May 2026.

Four kinds of Ebola make people ill. One of them has all three doors open.

The Xpert Hemorrhagic Fever Panel is separate from the Xpert Ebola cartridge used in Bunia in May 2026. WHO says the panel detects Zaire, Sudan, Taï Forest and Bundibugyo viruses without distinguishing species. Results are presumptive; a negative result alone does not rule out infection. The FDA separately authorized the OraQuick Ebola 2.0 antigen test for defined specimens and settings in authorized laboratories. For Bundibugyo, the regulatory door stays shut: Ervebo is not licensed and clinical protection has not been demonstrated. The approved drugs are Inmazeb and Ebanga, both for Zaire only. On 1 September, WHO recommended Ervebo against Bundibugyo only in research protocols. Neither the EUL listing nor the EUA confirms test stock or use in Bunia.

The economics of proof

A drug is only proved during an outbreak

Ervebo, Inmazeb and Ebanga were approved on the strength of studies run on people during outbreaks. That is how anyone finds out whether an Ebola vaccine or treatment works: you give it to people who have the disease or are about to be exposed to it, and you compare what happens to them. There is no other place and no other moment to do it.

Ervebo exists because the West African epidemic between 2013 and 2016 left more than 11,000 dead and, with them, enough sick people for a trial. Inmazeb and Ebanga came out of the 2018 to 2020 outbreak in DR Congo.

Both previous Bundibugyo outbreaks were too small for that. The first, in Uganda in 2007 and 2008, had 131 reported cases and 42 deaths. The second, in DR Congo in 2012, had 62 cases and 34 deaths. There were never enough sick people to prove anything, and never enough well people for a manufacturer to sell to.

There is a European document that says this out loud. When the European Medicines Agency recommended the two-dose Ebola vaccine Zabdeno and Mvabea in May 2020, it wrote that the authorisation was granted under exceptional circumstances „because the applicant was able to demonstrate that it is not possible to conduct a randomised controlled study that might generate comprehensive clinical data on the efficacy of the new Ebola vaccine even after authorisation”. The regulator wrote down the trap in 2020 and licensed the product anyway.

The vaccines were never marketed in the European Union, according to EMA. On 1 May 2026 the European Commission withdrew the authorisation at the manufacturer’s request, for commercial reasons. Fourteen days later, DR Congo declared an Ebola outbreak.

Ebola countermeasures on the European and United States registers, 25 July 2026
ProductSpecies coveredStatus
ErveboZaireauthorised in the EU since November 2019
Zabdeno and MvabeaZaireEU authorisation withdrawn on 1 May 2026
InmazebZaireapproved in the United States, not in the EU
EbangaZaireapproved in the United States, not in the EU

The world’s filovirus kit is not a map of the dangerous viruses. It is a register of the outbreaks that grew large enough to be used as proof.

The three Bundibugyo outbreaks

The window

A treatment can only be proved while there are patients who can enter a trial.Every dot is one reported case.The first two outbreaks ended at 131 and 62 cases.There is no universal threshold: the number needed depends on the treatment, mortality and trial design.

2 July 2026PARTNERS opened in Bunia on 2 July 2026. The epidemiological situation reported for 1–2 July contained 1,481 confirmed cases in DR Congo, Uganda and France.

2 July 2026 PARTNERS begins enrolment 2007 and 2008 Uganda 2012 DR Congo 2026 DR Congo

131 reported cases. 42 deaths.

62 reported cases. 34 deaths.

As of 4 November, WHO reports 10,741 confirmed cases, 5,230 confirmed deaths, 2,888 recoveries and 539 suspected cases in DR Congo. Figures may be revised.

2 July: PARTNERS begins enrolling patients.

The third outbreak created the first window in which a trial could begin.

The 2007 and 2012 figures are reported cases from the US CDC. WHO data for 6 October give 8,728 confirmed cases, 4,205 deaths and 2,269 recoveries across 64 health zones in seven provinces. As an earlier reference, the DRC report with data through 16 September, relayed by ECDC on 18 September, gives 7,475 confirmed cases and 3,605 deaths across seven provinces. The government considered the peak reached in August, but the independent Africa CDC assessment of 17 September said the data did not yet allow that conclusion. The daily series may be revised retrospectively.

Uganda, 2022

Success destroyed the evidence

4years between the drug and the question still unanswered

In 2022 Uganda had an outbreak of Sudan ebolavirus. There was no approved treatment for Sudan either, so some patients were given MBP134, a pair of antibodies designed to cover several ebolavirus species at once. It was given , outside any trial, because there was nothing else to give.

Uganda stopped the outbreak faster than anyone expected. The outbreak ended before anyone could find out whether the drug had worked.

In July 2026 MBP134 entered the first trial that tests it in patients, in Bunia. Same drug. Same question. Four years in between, and it took another outbreak.

24 August · first published human clinical data. A confirmed Bundibugyo case received MBP134, remdesivir and supportive care, recovered and was discharged. Separately, five contacts, one adult and four children, received MBP134 after exposure and remained free of disease with negative PCR tests during 21 days of follow-up. These are the first published clinical observations of MBP134 in Bundibugyo, but they do not yet show efficacy. There were no control groups, and randomized trial results are not available.

25 August 2026

What remains at Day 100

Day 100of 100Day 0 · 17 May 2026Day 100 · 25 August 2026

Day 100 · 25 August 2026. The 100 Days Mission clock for Bundibugyo has reached its final milestone. The table below preserves the historical Day 98 snapshot; IPPS’s official Day 100 assessment is summarised in the block that follows.

Historical snapshot · Day 98
SpeciesRapid test in the fieldLicensed vaccineApproved treatment
ZaireGeneXpert cartridgeErveboInmazeb, Ebanga
Sudannonenonenone
BundibugyoRADI kit, under validationnonenone
Taï Forestnonenonenone

The flat line is the negative result, the same trace as in the plot at the top. Here it means nothing exists.

  • On 2 July the first patient was enrolled in Bunia into PARTNERS, the trial testing MBP134 and remdesivir, separately and together.
  • On 14 July EBO-PEP began, giving obeldesivir, a drug taken by mouth, to people who have been exposed to the virus.
  • On 1 June, CEPI put money behind three candidate vaccines: up to 3.2 million dollars for IAVI, 8.6 million for Oxford with the Serum Institute of India, 50 million for Moderna.
  • On 13 July the University of Oxford announced the world’s first human trial of a Bundibugyo vaccine. Fifty healthy volunteers between 18 and 55, in Oxford. The announcement counts 57 days since the emergency was declared.
  • On 7 August WHO’s technical group recommended taking Ervebo directly into a Phase III study in the current outbreak to test possible cross-protection. Ervebo is not yet licensed for Bundibugyo.
  • 22 May–22 August · superseded version of the IHR Temporary Recommendations. The set issued by WHO on 22 May reached the automatic three-month limit under the International Health Regulations. The Emergency Committee met again on 18 August, and WHO published the updated set that replaces it on 24 August. The international emergency has a separate legal status and remains in force.
  • 21 August · the first doses reach DR Congo. More than 16,000 Ervebo doses arrived in Kinshasa. The DRC Ministry of Health and ACP give 16,520; AP and AFP reported 16,250. ACP describes this shipment as part of 50,120 doses expected between 21 and 24 August. WHO allocated 70,000 doses in total: 20,000 for the Phase III trial and 50,000 for frontline and health workers.
  • 22 August · available stock is smaller than the allocation. INSP’s director says the DRC currently has 20,750 doses available: 20,000 for the Phase III trial and 750 for frontline workers. The first announced strategy is a vaccination belt around Ituri to limit spread towards Tshopo, Haut-Uele and Bas-Uele. Ervebo remains unlicensed for Bundibugyo, and its clinical effectiveness against this species has not been demonstrated.
  • 24 August · current WHO Temporary Recommendations. The new document details surveillance, case detection, diagnosis, clinical care and infection control, and adds measures for public gatherings, domestic mobility and inland water transport. WHO explicitly maintains that there is still no approved vaccine or treatment for Bundibugyo and calls for head-to-head comparisons of field PCR platforms and robust clinical trials of candidate vaccines and therapeutics.
  • 27 August · administration begins. In Kisangani, the health minister officially launched vaccination for health workers and other frontline response workers; people who have had contact with patients are next. Ervebo is being used against Bundibugyo before efficacy for this species has been demonstrated: it remains licensed only for Zaire, and the Phase III study is meant to establish whether cross-protection exists. The BRAVO follow-up study, launched in Bunia on 19 September, follows 20,000 frontline workers over time; MSF does not present it as a randomized Phase III study. Tumaini, described by CEPI on 13 October, is a separate Phase II/III study still in preparation at the date of the announcement.
  • 28 August · WHO publishes Disease Outbreak News no. 616. With data through 26 August, WHO reports 5,794 confirmed cases, 2,786 confirmed deaths and 60 affected health zones in the DRC. Biena and Manguredjipa are the two new zones in North Kivu.
  • 28 August · WHO IHR Emergency Committee report. The outbreak remains a public health emergency of international concern and does not meet the criteria for a pandemic emergency. On 12 August, about 1,000 beds were available against an estimated need for 3,000; mortality-based modelling gave a 21-day doubling time and an Rt of 1.55. Models suggest three to four times as many infections as surveillance captures, with moderate confidence. WHO found no evidence of a fundamental change in the virus’s biology or modes of transmission.
  • 30 August · SitRep N°108/MVEBDB/30/08/2026 from the DRC National Institute of Public Health, published on 31 August. The tally reaches 6,100 confirmed cases and 2,950 confirmed deaths across 60 affected health zones; no new health zone was affected in the previous 24 hours.
  • 1 September · WHO tightens the Ervebo recommendation. The emergency guidance published on 1 September and dated 31 August says evidence remains insufficient to establish clinically meaningful protection against Bundibugyo and recommends using the vaccine only within research protocols.
  • 2 September · the official tally passes 3,000 deaths. Covering data through 31 August, the latest DRC Ministry of Health and National Institute of Public Health report, cited by Actualité.cd and independently confirmed by AP and Reuters, gives 6,186 confirmed cases, 3,007 deaths and 1,409 recoveries; about 830 people remain in isolation or Ebola treatment centres.
  • 3 September · ECDC updates its outbreak page. Congolese authorities reported 6,250 confirmed cases, including 3,039 deaths, with data through 1 September. ECDC gives 1,439 recoveries, 869 patients in isolation and 60 of 151 affected health zones, and notes that the figures remain under review and harmonisation.
  • 4 September · ECDC and WHO publish the same official tally. With data through 2 September, the DRC report reaches 6,342 confirmed cases and 3,072 deaths; 1,475 people have recovered, 770 patients are hospitalised in isolation and 60 of 151 health zones are affected. WHO Africa also reports the launch in Kinshasa of a revised 180-day multisectoral response plan.
  • 14 September · ECDC updates its outbreak page again. With data through 12 September, the DRC report reaches 7,200 confirmed cases and 3,475 deaths. There are 923 patients hospitalised in isolation, 88% of identified contacts are under follow-up, and 62 of 167 health zones are affected across seven provinces. ECDC notes that the figures remain under review and harmonisation.
  • 15 September · the tally and its interpretation separate. The UN/WHO briefing gives 7,258 confirmed cases and 3,510 deaths across seven provinces. The government says daily cases have fallen from about 120 to 80 and considers the peak passed, but WHO cautions that it is too early to declare a turning point. Some areas are improving while others continue to rise.
  • 17 September · Africa CDC says the peak is not yet demonstrated. The Emergency Consultative Group completes an independent scientific review: declines in some hotspots, including Ituri, are encouraging, but transmission is rising in some zones, especially North Kivu, and the available data do not confirm that the peak has been reached. The Group recommends keeping the continental emergency and intensifying the response.
  • 18 September · ECDC relays the new DRC tally. With data through 16 September, the report reaches 7,475 confirmed cases and 3,605 deaths, 71 cases and 32 deaths more than the previous report. There are 905 patients hospitalised in isolation, 1,798 recoveries, 87.6% of contacts under follow-up and 62 of 167 zones affected across seven provinces. ECDC notes that the figures remain under review and harmonisation.
  • 19 September · the BRAVO study begins in Bunia. MSF and Epicentre, with the DRC Ministry of Health, Africa CDC and INRB, launch BRAVO, a follow-up study for frontline workers in Ituri and North Kivu, covering 20,000 people over nine to twelve months: three months of Ervebo vaccination and at least six months of follow-up. The study gathers real-world data on the effect of Ervebo against Bundibugyo; participation and vaccination are voluntary. Ervebo remains licensed only for Zaire virus, and any benefit against Bundibugyo remains to be demonstrated. MSF does not present BRAVO as a randomized Phase III study. Tumaini, described by CEPI on 13 October, is a separate Phase II/III study still in preparation at the date of the announcement.
  • 26 September · NICD reports 8,067 cases, 3,901 deaths and 2,070 recoveries across seven provinces. No vaccine or treatment is approved for Bundibugyo virus.
  • 28 September · another treatment trial. NanoViricides, sponsor of the oral NV-387 trial, announces that enrolment and dosing began in Ituri around 23 September. Protocol PACTR202608748555077 provides for a Phase IIA safety and dose run-in, then a randomised, open-label Phase IIB efficacy evaluation with independent blinded-endpoint adjudication. The release reports no clinical results. When checked on 16 October, the registry still says “Not yet recruiting” and has no actual start date; the sources are not synchronized. The sponsor said on 13 October that Phase IIA was continuing. These announcements do not demonstrate efficacy or mean the treatment is approved.
  • 29 September · the UN Geneva briefing cites WHO as reporting more than 1,600 beds across 50 centres and nearly 400 trained workers; it does not state the observation date.
  • 30 September · a WHO Africa feature gives a dated series: 929 beds on 27 July and 1,510 on 21 September across 54 facilities in 34 health zones. On 21 September, 326 more beds were being installed and 146 were planned; the expansion needed more than 1,400 additional health professionals.
  • 8 October · WHO publishes its tally with data through 6 October: 8,728 confirmed cases, 4,205 deaths and 2,269 recoveries across 64 health zones in seven provinces. It says transmission remains intense nationally, although trends differ between areas.
  • 13 October · CEPI announces final preparations for Tumaini. Tumaini is a separate Phase II/III study to assess vaccine safety, immune responses and efficacy. On 13 October, CEPI announced final preparations and an expected start in the coming weeks, subject to ethical and regulatory approvals. Registry entry NCT07842107, last updated on 5 October and checked on 16 October, displayed “Not yet recruiting” and no results. A trial plan does not establish efficacy or constitute approval of a vaccine for Bundibugyo.
  • 16 October · ECDC publishes the DR Congo tally through 14 October: 9,277 confirmed cases, 4,478 deaths and 2,486 recoveries across 65 health zones in seven provinces. Separately, WHO confirms Kenya’s third case, bringing the total to three cases and one death; the latest two cases were detected in quarantine.
  • 16 October · DR Congo INSP SitRep 155, dated for publication on 17 October, records 9,415 confirmed cases, 4,536 deaths and 2,522 recoveries across 66 health zones in eight provinces. Nord-Ubangi is the eighth affected province; Wapinda health zone reports two cases, including one death.
  • 17 October · Kenya’s Ministry of Health confirms four new cases of Bundibugyo Ebola: three health workers who cared for the first patient and one relative. The total reaches seven confirmed cases and one death. All four developed symptoms in quarantine and were quickly isolated. The Ministry reports 128 of 130 contacts traced and quarantined, with no evidence of community transmission at that date. The statement does not attribute the infections to a GeneXpert failure.
  • 18 October · Kenya’s Ministry of Health announces one additional Ebola case, confirmed by Director-General for Health Patrick Amoth. The total reaches eight confirmed cases. The case count alone does not establish community transmission.
  • 19 October · WHO Africa External Situation Report 23 records 9,637 confirmed cases and 4,646 confirmed deaths in DR Congo. This is retained as a dated snapshot; the next WHO tally uses data through 20 October.
  • 20 October · WHO reports nine cases in Kenya, including one death; the other eight are epidemiologically linked to the imported case. There is no evidence of transmission outside the cluster.
  • 20 October · WHO and Nigeria’s Federal Ministry of Health confirm one imported, laboratory-confirmed case in FCT/Abuja. The patient had recently travelled from Uganda; symptoms began on 7 October, and she sought care on 11 October. 44 contacts were identified and the likely source of infection remains under investigation. One imported case alone does not establish community transmission in Nigeria. Neither statement says the patient was missed by GeneXpert.
  • 23 October · WHO publishes its DR Congo tally through 20 October: 9,704 confirmed cases, 4,687 deaths and 2,595 recoveries across 66 health zones in eight provinces. WHO says the figures may be revised. This remains a dated snapshot.
  • 23 October · the Tumaini clinical trial begins in Bunia. WHO reports that the first participants were enrolled; the Institute of Tropical Medicine Antwerp confirms the first participant was vaccinated. The trial will evaluate multiple vaccine candidates. Its start does not demonstrate efficacy or mean a vaccine is approved for Bundibugyo.
  • 23 October · WHO reports 2,000 beds available against the 3,000 target stated by its incident manager. Occupancy was falling in previously affected areas, but newly affected, remote areas still needed beds and medical teams. At Biacato, WHO cited 70 confirmed cases without an Ebola treatment centre, with people treated in suboptimal conditions; in North Kivu, patients visited two to five facilities before referral to an Ebola treatment centre. The transcript does not date the bed inventory or define its counting method, so it is not directly comparable with the dated September series.
  • 26 October · WHO Africa reports that 20 contacts associated with Kenya’s first imported case completed 21 days of monitoring and were released from quarantine; 98 remained. Eight contacts had developed symptoms and tested positive; all were already in quarantine. Kenya reported nine confirmed cases and two deaths. WHO said all nine were part of one connected group and found no evidence of community transmission.
  • 31 October · WHO’s daily epidemiological table dates the DR Congo row to 28 October: 601 suspected cases, 10,274 confirmed cases, 4,992 deaths and 2,766 recoveries. In the same table, Kenya is dated 29 October and Nigeria 27 October; those country rows do not form a same-day total. WHO says the DRC tally may be revised.
  • 4 November · recommendation for two vaccine candidates. On 4 November, WHO recommended adding two vaccine candidates designed for Bundibugyo to Tumaini: ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469. Their entry into the trial is subject to national approvals. The recommendation does not demonstrate efficacy or authorize these vaccines for Bundibugyo.

On that same 13 July, at Rwampara general hospital inside the epicentre, epidemiologists, case investigators, drivers and gravediggers went on strike because they had not been paid since the outbreak began. On Wednesday staff at Bunia general hospital struck too and blocked the entrance. Confirmed cases were passing 2,000 that week, with 754 dead.

The Oxford trial runs on healthy volunteers in a country with no Ebola. It shows whether that candidate is safe and whether it raises an immune response. Whether it protects anyone can only be learned where the disease is, which means Ituri, during the outbreak. Ervebo is at a different stage: on 20 August, WHO/SAGE supported limited use outside the study for health and frontline workers, while WHO recommended testing it directly in this outbreak. The WHO guidance published on 1 September and dated 31 August now recommends using it against Bundibugyo only within research protocols; it is not licensed or proven for Bundibugyo. If the outbreak is stopped before the Oxford study can answer the protection question, that candidate remains unlicensed. Oxford delivered in 57 days. The structure it delivered into is the part that does not hold. A Correspondence published in Nature Medicine on 26 August quantified that pressure using INSP data from 2 August: Ebola treatment centres in North Kivu were operating at 131.9% capacity, with 186 patients for 141 declared beds, while some centres in Ituri were above 200%; Nizi had reached 278%. The authors warn that overcrowding makes rapid, safe isolation harder and may sustain transmission. These figures describe operations on 2 August. The article is a Correspondence; it quantifies operational pressure without establishing how many infections overcrowding caused.

If too few people have your disease, nobody can prove a treatment works, so nobody makes one. Ebola is the most violent version of the logic that decides whether a drug exists for a rare disease on a children’s ward in Bucharest or in Bristol.

Audit

Sources

What this is and what it is not

WHO’s 4 November recommendation to expand Tumaini was checked separately on 7 November; entry of the new candidates remains subject to national approvals. Vaccine, treatment, Tumaini, NCT07842107 and NV-387 evidence retain their checks of 16 October 2026. Diagnostic products were rechecked on 7 November against WHO’s six-product list and separate seven-application table, both dated 2 November, and WHO notices about BioFire (19 October) and RADIONE (2 November, 12:48 CET). WHO’s RADIONE notice says the test detects RNA from Zaire, Sudan, Bundibugyo, Taï Forest and Reston. The six listed products and seven ongoing applications have different statuses and do not form a total of available tests. The copy does not claim stock, local availability or use; the 25 August IPPS snapshot remains historical. The epidemiological situation was rechecked on 7 November against WHO’s daily country table: DR Congo is dated 4 November, Kenya 5 November and Nigeria 4 November. Kenya’s contact details remain dated 26 October; Nigeria’s 44 contacts remain dated 20 October. Treatment capacity was rechecked on 27 October against the UN/WHO transcript of 23 October, which reported 2,000 beds against a 3,000 target but gave no inventory date or counting method. September observations remain dated references. The text covers the regulatory position in the European Union and United States. No human clinical review occurred.

What is written here is public information, not medical advice. Anyone who develops a fever after travelling in an area with Ebola should call ahead and say where they have been before walking into a waiting room.

The update made on 18 October used the Kenyan statement of 17 October, recovered in full from the official post: seven confirmed cases and one death. At that update, the DR Congo tally remained the ECDC snapshot through 14 October. Both observations are retained in the timeline. The Kenyan statement does not establish a link between infections and a false-negative GeneXpert result.

What kinds of claim are here

  • documented facthas a primary source, listed below
  • a number that movescarries its date beside it
  • editorial inferencejoins documented facts and is written as such

The outbreak

The detection gap

Diagnostics rechecked 7 November

Vaccines and treatments

History and virology

The outbreak status was rechecked on 7 November 2026 against WHO’s daily country table, with separate row dates: DR Congo 4 November, Kenya 5 November and Nigeria 4 November. Kenya’s contact details remain dated 26 October; Nigeria’s travel, symptom-onset and 44-contact details remain dated 20 October. The next epidemiological check is due by 8 November. Diagnostic products were rechecked on 7 November against WHO’s six-product list and separate seven-application table, both dated 2 November, and WHO’s 2 November RADIONE notice. Vaccine authorization and treatment claims retain their checks of 25 October. No human clinical review occurred. Tallies may be revised.